Last reviewed · How we verify

Cobimetinib, dexamethasone, ixazomib, pomalidomide

Multiple Myeloma Research Consortium · Phase 1 active Small molecule

Cobimetinib, dexamethasone, ixazomib, pomalidomide is a Small molecule drug developed by Multiple Myeloma Research Consortium. It is currently in Phase 1 development. Also known as: cobimetinib: Cotellic, GDC-0973, RG7420, ixazomib: Ninlaro, MLN2238, pomalidomide: Pomalyst.

At a glance

Generic nameCobimetinib, dexamethasone, ixazomib, pomalidomide
Also known ascobimetinib: Cotellic, GDC-0973, RG7420, ixazomib: Ninlaro, MLN2238, pomalidomide: Pomalyst
SponsorMultiple Myeloma Research Consortium
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cobimetinib, dexamethasone, ixazomib, pomalidomide

What is Cobimetinib, dexamethasone, ixazomib, pomalidomide?

Cobimetinib, dexamethasone, ixazomib, pomalidomide is a Small molecule drug developed by Multiple Myeloma Research Consortium.

Who makes Cobimetinib, dexamethasone, ixazomib, pomalidomide?

Cobimetinib, dexamethasone, ixazomib, pomalidomide is developed by Multiple Myeloma Research Consortium (see full Multiple Myeloma Research Consortium pipeline at /company/multiple-myeloma-research-consortium).

Is Cobimetinib, dexamethasone, ixazomib, pomalidomide also known as anything else?

Cobimetinib, dexamethasone, ixazomib, pomalidomide is also known as cobimetinib: Cotellic, GDC-0973, RG7420, ixazomib: Ninlaro, MLN2238, pomalidomide: Pomalyst.

What development phase is Cobimetinib, dexamethasone, ixazomib, pomalidomide in?

Cobimetinib, dexamethasone, ixazomib, pomalidomide is in Phase 1.

Related